Recombinant Human CD79B Protein, His-tagged, Site-specific PE-Labeled

• Cat.No.: CD79B-4667H
• Product Overview: Site-specific PE-Labeled Recombinant Human CD79B Protein(P40259-1)(Ala 29 - Asp 159), fused with C-terminal His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: C-His
• Protein length: Ala 29 - Asp 159
• Conjugation/Label: Site-specific PE
• Form: Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4.
• Molecular Mass: The protein has a calculated MW of 18.8 kDa.
• Storage: For long term storage, the product should be stored at lyophilized state at -20°C or lower.
  Please protect from light and avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20°C to -70°C for 12 months in lyophilized state;
  -70°C for 6 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CD79B CD79b molecule, immunoglobulin-associated beta [ Homo sapiens ]
• Official Symbol: CD79B
• Synonyms: CD79B; CD79b molecule, immunoglobulin-associated beta; CD79B antigen (immunoglobulin associated beta) , IGB; B-cell antigen receptor complex-associated protein beta chain; B29; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta); IGB; AGM6
• Gene ID: 974
• mRNA Refseq: NM_000626
• Protein Refseq: NP_000617
• MIM: 147245
• UniProt ID: P40259

Reviews

04/26/2023

Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

11/16/2021

The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

10/26/2018

One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

Q&As

How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies?

CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

How does CD79B contribute to the development of personalized treatment strategies for B cell diseases?

Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies?

Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker?

Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs?

Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.